drugset / Trial / NCT01223729

Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy

NCT01223729

Completed 67 enrolled University of Catania
RandomizedParallel-groupDouble-blindTreatment

Summary

Minimal hepatic encephalopathy represents a common complication present in well-compensated cirrhotic patients that impairs patients daily functioning and health-related quality of life. Acetyl-L-carnitine has been shown to be useful in improving blood ammonia and cognitive functions in cirrhotic patients with minimal hepatic encephalopathy. This study evaluated the effects of acetyl-L-carnitine treatment on health related quality of life and on depression in patients with minimal hepatic encephalopathy.

Timeline

Start
2002-04
Primary completion
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetylcarnitine Small molecule 2 g